About: Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis
Creator	Benden, Christian Haile, Sarah Dressel, Holger Radtke, Thomas
Source	Elsevier; PMC
abstract	Background Severe acute respiratory syndrome – coronavirus-2 (SARS-CoV-2) has caused a pandemic threatening the life of people with chronic respiratory diseases including cystic fibrosis (CF). This study was designed to investigate health-related aspects of individuals with CF, with and without lung transplantation (LTX), their communication with their specialist healthcare providers during the pandemic, potential changes in peoples’ individual therapy regimes and daily physical activity levels. Methods A web-based survey was conducted among Swiss adults with CF with and without LTX, study period from March 16th, 2020 – the day the “extraordinary situation” was officially declared in Switzerland introducing stringent measures protecting the public – until May 16th, 2020. Results 327 individuals (25% LTX recipients) were included, 45 individuals reported coronavirus-2019 disease (COVID-19) like symptoms. Of 28 subjects tested, only three subjects were tested positive, all with mild symptoms, no hospitalization required. Almost half of the survey respondents (45%) reported to undertake less physical activity during the lockdown, while 79% and 91% of participants reported no change in traditional airway clearance and inhalation therapies, respectively. Distress regarding a potential SARS-CoV-2 infection or worsening of lung disease were no major concerns for subjects. Conclusions Our study reveals that the direct impact of SARS-CoV-2 on clinical outcomes of individuals with CF was mild although people with chronic lung diseases like CF are considered a high-risk population; overall, this is reassuring. However, strict lockdown measures substantially affected peoples’ physical activity levels, a vital cornerstone of CF therapy; and this is worrisome.
has issue date	2020-08-28(xsd:dateTime)
bibo:doi	10.1016/j.jcf.2020.08.013
has license	els-covid
sha1sum (hex)	abf383e2eaa384c064b771d4cb4ce549c55f07bd
schema:url	https://doi.org/10.1016/j.jcf.2020.08.013
resource representing a document's title	Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis
has PubMed Central identifier	PMC7455146
schema:publication	J Cyst Fibros
resource representing a document's body	covid:abf383e2eaa384c064b771d4cb4ce549c55f07bd#body_text
is schema:about of	named entity 'adults' named entity 'COVID-19' named entity 'physical activity' named entity 'LTX' named entity 'COVID-19' named entity 'Kruskal-Wallis test' named entity 'May 16' named entity 'cardiovascular disease' named entity 'Thoracic' named entity 'cystic fibrosis' named entity 'LTX' named entity 'health care' named entity 'lung disease' named entity 'COVID-19' named entity 'non-medical' named entity 'LTX' named entity 'physical activity' named entity 'LTX' named entity 'LTX' named entity 'VAS' named entity 'long-term' named entity 'LTX' named entity 'fatigue' named entity 'SARS-CoV-2' named entity 'social distancing' named entity 'infection' named entity 'intellectual property' named entity 'lung' named entity 'general population' named entity 'Cystic Fibrosis' named entity 'diabetes' named entity 'sequelae' named entity 'recall bias' named entity 'physical activity' named entity 'SARS-CoV-2' named entity 'LTX' named entity 'SOT' named entity 'SARS-CoV-2' named entity 'selection bias' named entity 'Lung Transplantation' named entity 'comorbidities' named entity 'LTX' named entity 'solid organ transplant' named entity 'North America' named entity 'social desirability bias' named entity 'COVID-19' named entity 'France' named entity 'organ transplantation' named entity 'SOT' named entity 'cystic fibrosis' named entity 'SARS-CoV-2' named entity 'Italy' named entity 'CFCH' named entity 'ggplot2' named entity 'SARS-CoV-2' named entity 'VAS' named entity 'lung diseases' named entity 'LTX' named entity 'Switzerland' named entity 'LTX' named entity 'EQ-5D' named entity 'LTX' named entity 'VAS' named entity 'lung disease' named entity 'LTX' named entity 'allograft' named entity 'China' named entity 'physical activity' named entity 'well-being' named entity 'physical activity' named entity 'EQ-5D' named entity 'diabetes' named entity 'SARS-CoV-2' named entity 'Europe' named entity 'lung diseases' named entity 'non-medical' named entity 'COVID-19' named entity 'Europe' named entity 'Italian' named entity 'lung diseases'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software